KROS · NASDAQ
Keros Therapeutics (KROS) Stock Price & Fundamentals
Keros Therapeutics (KROS) closed at $657.54 on Oct 9, 2026, up 0.34% from the previous close of $655.30.
Share price, past year
1Y −1.36%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $657.54 |
| Sep 30, 2026 | $645.74 |
| Aug 31, 2026 | $688.02 |
| Jul 31, 2026 | $700.60 |
| Jun 30, 2026 | $700.06 |
| May 29, 2026 | $692.15 |
| Apr 30, 2026 | $744.34 |
| Mar 31, 2026 | $746.32 |
| Feb 27, 2026 | $725.89 |
| Jan 30, 2026 | $706.33 |
| Dec 31, 2025 | $746.99 |
| Nov 28, 2025 | $722.70 |
| Oct 31, 2025 | $689.57 |
Key statistics
- Market cap
- $13.04B
- P/E (TTM)
- —
- EPS (TTM)
- −$3.22
- Revenue (TTM)
- $14.54M
- Net income (TTM)
- −$83.16M
- Shares outstanding
- 19.8M
- Dividend yield
- —
- 52-week range
- $641.17 – $769.89
Keros Therapeutics's market cap is $13.04B, based on a share price of $657.54 and 19.8M shares outstanding as of Jun 30, 2026.
Financials
Keros Therapeutics reported revenue of $243.86M for fiscal 2025.
Keros Therapeutics earned net income of $87.01M in fiscal 2025, a net margin of 35.7%.
Fiscal 2025 revenue was the highest in the 7 years shown.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $243.86M | — | $87.01M | 35.7% | $2.30 | $105.95M |
| FY2024ended Dec 31, 2024 | $0.00 | −100.0% | −$187.35M | — | −$5.00 | −$162.80M |
| FY2023ended Dec 31, 2023 | $151.00K | — | −$152.99M | −101,319.2% | −$5.20 | −$126.97M |
| FY2022ended Dec 31, 2022 | $0.00 | −100.0% | −$104.68M | — | −$4.15 | −$71.30M |
| FY2021ended Dec 31, 2021 | $20.10M | — | −$58.74M | −292.3% | −$2.52 | −$63.17M |
| FY2020ended Dec 31, 2020 | $0.00 | −100.0% | −$45.36M | — | −$2.93 | −$37.19M |
| FY2019ended Dec 31, 2019 | $10.00M | — | −$12.34M | −123.4% | −$6.08 | −$16.27M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $0.00 | −$28.71M | −$1.45 |
| Q1 FY2026ended Mar 31, 2026 | $32.00K | −$23.71M | −$1.21 |
| Q4 FY2025ended Dec 31, 2025 | $380.00K | −$23.46M | −$0.38 |
| Q3 FY2025ended Sep 30, 2025 | $14.12M | −$7.28M | −$0.18 |
| Q2 FY2025ended Jun 30, 2025 | $18.17M | −$30.70M | −$0.76 |
| Q1 FY2025ended Mar 31, 2025 | $211.19M | $148.45M | $3.62 |
| Q4 FY2024ended Dec 31, 2024 | $0.00 | −$46.03M | −$1.13 |
| Q3 FY2024ended Sep 30, 2024 | $0.00 | −$52.96M | −$1.41 |
Company profile
- Name
- Keros Therapeutics, Inc.
- Ticker
- KROS
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 1050 Waltham Street, Suite 302, Lexington, MA 02421
- Fiscal year ends
- December
- SEC CIK
- 0001664710
Recent SEC filings
- Sep 29, 2026
- Sep 28, 2026
- Sep 8, 2026
- Aug 3, 2026
- Aug 3, 2026
- Aug 3, 2026
- Jul 30, 2026
- Jul 22, 2026
Frequently asked questions
What is Keros Therapeutics's stock price?
Keros Therapeutics (KROS) closed at $657.54 on Oct 9, 2026, up 0.34% from the previous close of $655.30.
What is Keros Therapeutics's market cap?
Keros Therapeutics's market cap is $13.04B, based on a share price of $657.54 and 19.8M shares outstanding as of Jun 30, 2026.
How much revenue does Keros Therapeutics make?
Keros Therapeutics reported revenue of $243.86M for fiscal 2025.
Does Keros Therapeutics pay a dividend?
Keros Therapeutics's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Keros Therapeutics, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures